Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Respira Therapeutics Enters into Agreement with Gossamer Bio Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On?Demand Vardenafil for Pulmonary Hypertension
Independent CTRI Testing Indicates RZOLV Exhibits Dramatically Lower Acute Trout Toxicity Than Cyanide Reference
FPX Nickel and JOGMEC Delineate Multiple Awaruite Nickel Targets at the Expanded Klow Property in British Columbia
